Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pacira Biosciences Inc.
Headquarters: Parsippany, NJ, United States of America
Website: http://www.pacira.com
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Frank D. Lee, MBA
Number Of Employees: 790
Enterprise Value: $1,025,493,800
PE Ratio: -10.59
Exchange/Ticker 1: NASDAQ:PCRX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,058,336,640
BioCentury | Jan 23, 2025
Management Tracks
New COOs for Vividion, Edgewise
Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx
BioCentury | Dec 23, 2023
Management Tracks
Pacira names Lee CEO, Hastings chair
Plus: CRISPR’s CMO to depart and a new CFO for Alterity
BioCentury | Sep 27, 2023
Management Tracks
Morphic CEO Tipirneni taking medical leave of absence
Plus: David Stack to retire as chair, CEO of Pacira and updates from AM-Pharma, Invitae, Syneos and Faeth
BioCentury | Jul 19, 2022
Management Tracks
Sanofi’s Mei becomes CMO at Editas
Plus Ullmann to retire from J&J, and updates from Rome, Nuvation, Evelo and more
BioCentury | May 11, 2022
Product Development
May 10 Quick Takes: ‘molecular machines’ company MOMA lands $150M series B
Plus GPCR play Domain raises $42M and updates from OncoHost, Eisai, UCB, Idorsia and more
BioCentury | Jan 27, 2022
Management Tracks
Adaptimmune hires Piccina as CCO as it readies for first BLA
Plus Rowe new CSO at Cystic Fibrosis Foundation and updates from Immunovant, Senda, F2G and more
BioCentury | Jan 3, 2022
Product Development
What’s next for voltage-gated sodium channel blockers
Companies dial in subtype selectivity, explore new modalities, and move to more homogeneous trial populations
BioCentury | Oct 12, 2021
Finance
4Q financial markets preview, plus the future of NIH
Plus Novartis CEO’s view of translational science and this week’s Deal in Focus, Flexion-Pacira
BioCentury | Oct 11, 2021
Deals
With CVR, Pacira’s deal for Flexion could nearly double in size
Analgesics company Pacira adds marketed osteoarthritis therapy, with more upside for Flexion shareholders
BioCentury | Aug 3, 2021
Product Development
Ten PDUFA dates on deck in August: Data Byte
At least ten therapies have PDUFA dates this month, seven of which have been granted priority review by FDA. The agency is expected to announce its first two decisions on Friday for an NDA for
Items per page:
1 - 10 of 23